Literature DB >> 32607786

Berberine chloride suppresses non-small cell lung cancer by deregulating Sin3A/TOP2B pathway in vitro and in vivo.

Jian Chen1,2,3,4, Xiaofei Huang4, Cheng Tao1,2,3, Li Wang5, Zide Chen1, Xinping Li2,3, Qiang Zeng1,2,3, Min Ma6,7,8, Ren Zhang9,10, Zhengzhi Wu11,12.   

Abstract

PURPOSE: Berberine chloride (BBC) is a well-known plant isoquinoline alkaloid derived from Berberis aristata. In this study, we aim to explore the effect of BBC on non-small cell lung cancer (NSCLC), and further expound the underlying mechanism of BBC induces NSCLC cell death in vitro and in vivo.
METHODS: CCK-8 assay and colony formation assay were used to test the viability and colony formation ability of NSCLC cells. Apoptosis analysis was used to analyze the apoptotic cells. siRNAs were utilized to disturb the expression of Sin3A. qPCR and Western blot analysis were employed to determine mRNA and protein levels of related genes and proteins. Tumor xenografts model was used for in vivo detection.
RESULTS: BBC inhibited the proliferation and colony formation of human NSCLC cells in a dose- and time-dependent manner. In addition, BBC induced DNA double-stranded breaks (DSBs) through downregulating TOP2B level, leading to apoptosis in human NSCLC cells. The Chip-seq data of A549 cells obtained from the ENCODE consortium indicate that Sin3A binds on the promoters of TOP2B. Knockdown of Sin3A led to downregulation of TOP2B in human NSCLC cells. Furthermore, BBC decreased Sin3A expression and shortened the half-life of Sin3A, results in downregulation of TOP2B in human NSCLC cells.
CONCLUSION: In this study, we demonstrated a new mechanism that BBC suppresses human NSCLC by deregulating Sin3A/TOP2B pathway, leading to DNA damage and apoptosis in human NSCLC in vitro and in vivo.

Entities:  

Keywords:  Berberine; DNA damage; NSCLC; Sin3A; TOP2B

Mesh:

Substances:

Year:  2020        PMID: 32607786     DOI: 10.1007/s00280-020-04050-y

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  37 in total

Review 1.  Targeting DNA topoisomerase II in cancer chemotherapy.

Authors:  John L Nitiss
Journal:  Nat Rev Cancer       Date:  2009-04-20       Impact factor: 60.716

Review 2.  50 Years of progress in the systemic therapy of non-small cell lung cancer.

Authors:  Heather Wakelee; Karen Kelly; Martin J Edelman
Journal:  Am Soc Clin Oncol Educ Book       Date:  2014

3.  Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme.

Authors:  F H Drake; J P Zimmerman; F L McCabe; H F Bartus; S R Per; D M Sullivan; W E Ross; M R Mattern; R K Johnson; S T Crooke
Journal:  J Biol Chem       Date:  1987-12-05       Impact factor: 5.157

4.  Model for MLL translocations in therapy-related leukemia involving topoisomerase IIβ-mediated DNA strand breaks and gene proximity.

Authors:  Ian G Cowell; Zbyslaw Sondka; Kayleigh Smith; Ka Cheong Lee; Catriona M Manville; Malgorzata Sidorczuk-Lesthuruge; Holly Ashlene Rance; Kay Padget; Graham Hunter Jackson; Noritaka Adachi; Caroline A Austin
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-21       Impact factor: 11.205

5.  MEPE/OF45 as a new target for sensitizing human tumour cells to DNA damage inducers.

Authors:  P Zhang; H Wang; P S N Rowe; B Hu; Y Wang
Journal:  Br J Cancer       Date:  2010-02-09       Impact factor: 7.640

Review 6.  Cisplatin resistance and opportunities for precision medicine.

Authors:  Lauren Amable
Journal:  Pharmacol Res       Date:  2016-01-22       Impact factor: 7.658

Review 7.  Emerging Roles of Epigenetic Regulator Sin3 in Cancer.

Authors:  N Bansal; G David; E Farias; S Waxman
Journal:  Adv Cancer Res       Date:  2016-03-02       Impact factor: 6.242

8.  Cytoplasmic RAP1 mediates cisplatin resistance of non-small cell lung cancer.

Authors:  Lu Xiao; Xiaoying Lan; Xianping Shi; Kai Zhao; Dongrui Wang; Xuejun Wang; Faqian Li; Hongbiao Huang; Jinbao Liu
Journal:  Cell Death Dis       Date:  2017-05-18       Impact factor: 8.469

9.  Annexin A2 contributes to cisplatin resistance by activation of JNK-p53 pathway in non-small cell lung cancer cells.

Authors:  Xiaomin Feng; Hao Liu; Zhijie Zhang; Yixue Gu; Huisi Qiu; Zhimin He
Journal:  J Exp Clin Cancer Res       Date:  2017-09-08

Review 10.  TOP2B: The First Thirty Years.

Authors:  Caroline A Austin; Ka C Lee; Rebecca L Swan; Mushtaq M Khazeem; Catriona M Manville; Peter Cridland; Achim Treumann; Andrew Porter; Nick J Morris; Ian G Cowell
Journal:  Int J Mol Sci       Date:  2018-09-14       Impact factor: 5.923

View more
  5 in total

1.  Atovaquone and Berberine Chloride Reduce SARS-CoV-2 Replication In Vitro.

Authors:  Bruno A Rodriguez-Rodriguez; Maria G Noval; Maria E Kaczmarek; Kyung Ku Jang; Sara A Thannickal; Angelica Cifuentes Kottkamp; Rebecca S Brown; Margaret Kielian; Ken Cadwell; Kenneth A Stapleford
Journal:  Viruses       Date:  2021-12-04       Impact factor: 5.048

2.  Berberine Inhibits FOXM1 Dependent Transcriptional Regulation of POLE2 and Interferes With the Survival of Lung Adenocarcinoma.

Authors:  Lulu Ni; Ping Sun; Xiaochun Fan; Zhongjie Li; Hongli Ren; Jiangan Li
Journal:  Front Pharmacol       Date:  2022-01-31       Impact factor: 5.810

3.  Berberine induces non-small cell lung cancer apoptosis via the activation of the ROS/ASK1/JNK pathway.

Authors:  Qianqian Chen; Yaqin Hou; Dan Li; Zhou Ding; Xiao Xu; Bingjie Hao; Qing Xia; Ming Li; Lihong Fan
Journal:  Ann Transl Med       Date:  2022-04

Review 4.  Anticancer Effects and Mechanisms of Berberine from Medicinal Herbs: An Update Review.

Authors:  Ruo-Gu Xiong; Si-Yu Huang; Si-Xia Wu; Dan-Dan Zhou; Zhi-Jun Yang; Adila Saimaiti; Cai-Ning Zhao; Ao Shang; Yun-Jian Zhang; Ren-You Gan; Hua-Bin Li
Journal:  Molecules       Date:  2022-07-15       Impact factor: 4.927

5.  Cancer stemness-associated LINC02475 serves as a novel biomarker for diagnosis and prognosis prediction of hepatocellular carcinoma.

Authors:  Xian Lin; Lianxiang Luo; Yujiao Zou; Jian Chen
Journal:  Front Genet       Date:  2022-09-02       Impact factor: 4.772

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.